[go: up one dir, main page]

EP1545627A4 - TARGETED TUMOR THERAPY USING RECOMBINANT ADENOVIRUS VECTORS WITH SELECTIVE REPLICATION IN THE HYPOXIC REGIONS OF TUMORS - Google Patents

TARGETED TUMOR THERAPY USING RECOMBINANT ADENOVIRUS VECTORS WITH SELECTIVE REPLICATION IN THE HYPOXIC REGIONS OF TUMORS

Info

Publication number
EP1545627A4
EP1545627A4 EP03799374A EP03799374A EP1545627A4 EP 1545627 A4 EP1545627 A4 EP 1545627A4 EP 03799374 A EP03799374 A EP 03799374A EP 03799374 A EP03799374 A EP 03799374A EP 1545627 A4 EP1545627 A4 EP 1545627A4
Authority
EP
European Patent Office
Prior art keywords
vectors
tumors
recombinant adenovirus
adenovirus vectors
tumor therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03799374A
Other languages
German (de)
French (fr)
Other versions
EP1545627A2 (en
Inventor
Chuan-Yuan Li
Qian Huang
Mark W Dewhirst
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of EP1545627A2 publication Critical patent/EP1545627A2/en
Publication of EP1545627A4 publication Critical patent/EP1545627A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The presently claimed subject matter provides conditionally replication competent adenoviral vectors that confer selective cytotoxicity on cells expressing HIF-1 by infecting cells that allow HIF-1 inducible promoters present within the vectors to function. Also provided are compositions and host cells based upon the vectors, as well as methods of propagating and using the vectors. The presently claimed subject matter further provides a method of inhibiting tumor growth by co-infecting cells in a tumor with a conditionally replication competent adenovirus vector in conjunction with a replication deficient adenovirus vector.
EP03799374A 2002-10-01 2003-10-01 TARGETED TUMOR THERAPY USING RECOMBINANT ADENOVIRUS VECTORS WITH SELECTIVE REPLICATION IN THE HYPOXIC REGIONS OF TUMORS Withdrawn EP1545627A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41531902P 2002-10-01 2002-10-01
US415319P 2002-10-01
PCT/US2003/031097 WO2004031357A2 (en) 2002-10-01 2003-10-01 Targeted tumor therapy by use of recombinant adenovirus vectors that selectively replicate in hypoxic regions of tumors

Publications (2)

Publication Number Publication Date
EP1545627A2 EP1545627A2 (en) 2005-06-29
EP1545627A4 true EP1545627A4 (en) 2006-12-27

Family

ID=32069840

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03799374A Withdrawn EP1545627A4 (en) 2002-10-01 2003-10-01 TARGETED TUMOR THERAPY USING RECOMBINANT ADENOVIRUS VECTORS WITH SELECTIVE REPLICATION IN THE HYPOXIC REGIONS OF TUMORS

Country Status (7)

Country Link
US (2) US20060099709A1 (en)
EP (1) EP1545627A4 (en)
JP (1) JP2006500956A (en)
CN (1) CN1720066B (en)
AU (1) AU2003277191A1 (en)
CA (1) CA2501010A1 (en)
WO (1) WO2004031357A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003222427B8 (en) 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US8071740B2 (en) 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
DE60237777D1 (en) 2001-10-19 2010-11-04 Vascular Biogenics Ltd EFFECTS AND METHODS FOR THE TARGETED DOWN ALLGATION OF ANGIOGENESIS AND CANCER THERAPY
WO2005054467A1 (en) 2003-12-03 2005-06-16 Chugai Seiyaku Kabushiki Kaisha EXPRESSION SYSTEM WITH THE USE OF MAMMALIAN β-ACTIN PROMOTER
WO2006095846A1 (en) 2005-03-11 2006-09-14 Kansai Technology Licensing Organization Co., Ltd. Model animal in which state of disease condition is observable in real time, gene construct for achieving the same and use of the same
ES2276623B1 (en) * 2005-12-12 2008-06-01 Proyecto De Biomedicina Cima, S.L NEW ADENOVIRUS RECOMBINANTS OF CONDITIONED REPLICATION (CRAD).
US20100316609A1 (en) * 2006-10-18 2010-12-16 University Of Rochester Conditionally Replicating Viruses for Cancer Therapy
WO2008136213A1 (en) * 2007-04-27 2008-11-13 Oncolys Biopharma Inc. Radiosensitivity-enhancing agent
EP2606137B1 (en) 2010-08-16 2018-08-01 Salk Institute For Biological Studies Anti-cancer adenoviruses
WO2013138650A1 (en) * 2012-03-14 2013-09-19 Salk Institute For Biological Studies Adenoviral tumor diagnostics
CA2903582C (en) 2013-03-14 2021-06-08 Salk Institute For Biological Studies Oncolytic adenovirus compositions
CN103611168A (en) * 2013-12-02 2014-03-05 东南大学 Composite magnetic nanoparticles for targeted therapy of liver cancer and preparation method thereof
WO2017039313A1 (en) * 2015-09-01 2017-03-09 한양대학교 산학협력단 Antitumor immunity enhancing composition containing adenovirus simultaneously expressing il-12 and shvegf
KR102471633B1 (en) 2016-02-23 2022-11-25 솔크 인스티튜트 포 바이올로지칼 스터디즈 Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
EP3532082A4 (en) 2016-12-12 2020-08-26 Salk Institute for Biological Studies SYNTHETIC ADENOVIRUS DIRECTIVE TO TUMORS AND USES THEREOF
JP7264329B2 (en) * 2017-05-17 2023-04-25 シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） Generation of a Synthetic Promoter (SYN+PRO) Inducible by Activation of Mammalian T Cells to Improve T Cell Therapy
AU2019394015A1 (en) * 2018-12-04 2021-06-10 Sirion Biotech Gmbh Viral transduction using poloxamines
WO2023214183A2 (en) 2022-05-06 2023-11-09 Antibody Analytics Limited Chemically induced proximity systems
WO2024119387A1 (en) * 2022-12-07 2024-06-13 上海鑫湾生物科技有限公司 System for controlling target gene expression in response to hypoxic environment and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2218610A1 (en) * 1995-04-17 1996-10-24 Board Of Regents, The University Of Texas System An adenovirus helper-virus system
US6403370B1 (en) * 1997-02-10 2002-06-11 Genstar Therapeutics Corporation Oncolytic/immunogenic complementary-adenoviral vector system
US6900049B2 (en) * 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
AU2001245550A1 (en) * 2000-03-09 2001-09-17 Lee Walters Applications of immune system tolerance to treatment of various diseases
DE60137137D1 (en) * 2000-09-26 2009-02-05 Univ Emory VIRUSES AGAINST HYPOXIC CELLS AND TISSUE

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GRIFFITHS L ET AL: "THE MACROPHAGE - A NOVEL SYSTEM TO DELIVER GENE THERAPY TO PATHOGOLICAL HYPOXIA", GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 7, no. 3, February 2000 (2000-02-01), pages 255 - 262, XP008009954, ISSN: 0969-7128 *
KOSHIKAWA N ET AL: "THERAPEUTIC EFFICACY OF THE SUICIDE GENE DRIVEN BY THE PROMOTER OF VASCULAR ENDOTHELIAL GROWTH FACTOR GENE AGAINST HYPOXIC TUMOR CELLS", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 60, no. 11, 1 June 2000 (2000-06-01), pages 2936 - 2941, XP001024127, ISSN: 0008-5472 *
KRUYT F A E ET AL: "Toward a new generation of conditionally replicating adenoviruses: Pairing tumor selectivity with maximal oncolysis", HUMAN GENE THERAPY, MARY ANN LIEBERT, NEW YORK ,NY, US, vol. 13, no. 4, 1 March 2002 (2002-03-01), pages 485 - 495, XP002291269, ISSN: 1043-0342 *
KURIHARA T ET AL: "Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressiong the MUC1 antigen", JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, vol. 106, no. 6, September 2000 (2000-09-01), pages 763 - 771, XP002242916, ISSN: 0021-9738 *

Also Published As

Publication number Publication date
WO2004031357A2 (en) 2004-04-15
CN1720066A (en) 2006-01-11
JP2006500956A (en) 2006-01-12
CA2501010A1 (en) 2004-04-15
WO2004031357A3 (en) 2004-07-15
CN1720066B (en) 2012-05-23
US20060099709A1 (en) 2006-05-11
US20100151576A1 (en) 2010-06-17
AU2003277191A1 (en) 2004-04-23
AU2003277191A8 (en) 2004-04-23
EP1545627A2 (en) 2005-06-29

Similar Documents

Publication Publication Date Title
EP1545627A4 (en) TARGETED TUMOR THERAPY USING RECOMBINANT ADENOVIRUS VECTORS WITH SELECTIVE REPLICATION IN THE HYPOXIC REGIONS OF TUMORS
CA2761183C (en) Oncolytic adenoviruses for treating cancer
Deng et al. Oncolytic efficacy of thymidine kinase-deleted vaccinia virus strain Guang9
WO2002024640A3 (en) Recombinant adenovirus vectors that are replication-competent in tert-expressing cells
WO2006014729A3 (en) Inhibitors of angiopoietin-like 4 protein, combinations, and their use
CA2278616A1 (en) Adenoviruses having altered hexon proteins
WO2005118825A3 (en) Chimeric adenoviruses for use in cancer treatment
CA2343135A1 (en) Adenovirus vectors containing cell status-specific response elements and methods of use thereof
WO2003023000A3 (en) Linear dna fragments for gene expression
Terazaki et al. An optimal therapeutic expression level is crucial for suicide gene therapy for hepatic metastatic cancer in mice
WO2003092579A3 (en) Compositions and methods for treating cancer with an oncolytic viral agent
JP2004501650A5 (en)
WO2001004282A3 (en) Replication-competent anti-cancer vectors
AU5587198A (en) Methods for preparing nucleotide integrases
WO2000056866A3 (en) Akt-3 nucleic acids, polypeptides, and uses thereof
WO2005060515A3 (en) An oncolytic adenovirus
WO2020186207A8 (en) Non-viral dna vectors and uses thereof for expressing fviii therapeutics
CA2449013A1 (en) Viral mutants that selectively replicate in targeted human cancer cells
WO2004035616A3 (en) Adenovirus expressing genes in reverse order and use thereof
Sutter et al. Gene therapy for gastric cancer: is it promising?
WO2004018627A3 (en) Methods for propagating adenovirus and virus produced thereby
ZA200202413B (en) Cell-specific and/or tumor-specific promoter retargeting of herpes gamma 34.5 gene expression.
WO2003092598A3 (en) Treatment for pompe disease
Kwon et al. In vivo antitumor effect of herpes simplex virus thymidine kinase gene therapy in rat hepatocellular carcinoma: feasibility of adenovirus-mediated intra-arterial gene delivery
AU2003259761A1 (en) Enhancement of adenoviral oncolytic activity in prostate cells by modification of the e1a gene product

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050414

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1074387

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20061124

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/861 20060101ALI20061120BHEP

Ipc: C12N 5/10 20060101ALI20061120BHEP

Ipc: A61K 48/00 20060101AFI20050420BHEP

17Q First examination report despatched

Effective date: 20070419

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100501

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1074387

Country of ref document: HK